Cidara Therapeutics (CDTX) Misses Q2 EPS by 1c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.61 million versus the consensus estimate of $11.55 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• The Fed is hiking. Why isn't UBS worried about stocks?
• Faraday Future says it regained Nasdaq compliance after equity shortfall